Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 15 to 23 amino acid residues in defined sequence
Reexamination Certificate
2008-05-13
2008-05-13
Harris, Alana M. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
15 to 23 amino acid residues in defined sequence
C530S327000, C530S303000, C514S002600, C514S013800, C514S014800
Reexamination Certificate
active
07371813
ABSTRACT:
New methods for the treatment of human disease are provided. IGFBP-3 is administered together with a co-administered agent to subjects having disease, thereby alleviating the symptoms of the disease, under conditions where administration of IGFBP-3 alone at the maximum practicable dose has no measurable beneficial effect on the disease condition.
REFERENCES:
patent: 5187151 (1993-02-01), Clark et al.
patent: 5328891 (1994-07-01), Baxter et al.
patent: 5407913 (1995-04-01), Sommer et al.
patent: 5527776 (1996-06-01), Carlino et al.
patent: 5643867 (1997-07-01), Maack et al.
patent: 5681818 (1997-10-01), Spencer et al.
patent: 5723441 (1998-03-01), Higley et al.
patent: 5840673 (1998-11-01), Buckbinder et al.
patent: 5861273 (1999-01-01), Olson et al.
patent: 5914254 (1999-06-01), Mascarenhas et al.
patent: 6015786 (2000-01-01), Mascarenhas et al.
patent: 6017885 (2000-01-01), Bagi et al.
patent: 6025332 (2000-02-01), Mascarenhas
patent: 6040292 (2000-03-01), Sommer
patent: 6046033 (2000-04-01), Goto et al.
patent: 6368831 (2002-04-01), Maurer et al.
patent: 6887851 (2005-05-01), Mascarenhas
patent: 6914049 (2005-07-01), Mascarenhas
patent: 2003/0035788 (2003-02-01), Mascarenhas
patent: 199 51 824 (2001-05-01), None
patent: 0 128 733 (1984-12-01), None
patent: WO 95/03817 (1995-02-01), None
patent: WO 95/13823 (1995-05-01), None
patent: WO 96/02565 (1996-02-01), None
patent: WO 99/63086 (1999-12-01), None
patent: WO 00/20023 (2000-04-01), None
patent: WO 00/20024 (2000-04-01), None
patent: WO 02/24216 (2002-03-01), None
Forssmann, Accession No. AAY25506; DE19757250; published Jul. 1, 1999.
Rosenzwig, Accession No. AAB09675; WO 2000/23469; published Apr. 17, 2000.
Lalou, C. et al., Endocrinology, 137(8): 3206-3212, 1996.
Sigma Catalog, Sigma Chemical Company, 1994, p. 643
Adams, S. et al. (1995). “Pharmacokinetics and Bioavailability of rhIGF-I/IGFBP-3 in the Rat and Monkey,”Progress in Growth Factor Research6(2-4):347-356.
Ausubel, F. et al. (1987).Current Protocols in Molecular Biology. Green Publishing Associates and Wiley-Interscience, John Wiley & Sons. total pp. 6 (Table of Contents).
Baxter, R. C. et al. (Jul. 1989). “High Molecular Weight Insulin-Like Growth Factor Binding Protein Complex: Purification and Properties of The Acid-Labile Subunit From Human Serum,”The J. Biol. Chem. 264(20):11843-11848.
Baxter, R.C. (1988). “Characterization of the Acid-Labile Subunit of the Growth Hormone—Dependent Insulin-Like Growth Factor Binding Protein Complex,”J. of Clin. Endocrinol. and Metab. 67(2):265-272.
Baxter, R.C. et al. (Sep. 1986). “Growth Hormone-Dependent Insulin-Like Growth Factor (IGF) Binding Protein From Human Plasma Differs from Other Human IGF Binding Proteins,”Biochem. and Biophys. Res. Comm. 139(3):1256-1261.
Blum, W.F. and Ranke, M.B. (1991). “Plasma IGFBP-3 Levels as Clinical Indicators”In Modern Concepts of Insulin -Like Growth Factors: Plasma IGFBP-3 Levels as Clinical Indicators. E. M. Spencer, ed., Elsevier, New York. pp. 381-393.
Buckbinder, L. et al. (1995). “Induction of the Growth Inhibitor IGF-Binding Protein 3 by P53,”Nature377(6550): 646-649.
Butler, A. et al. (Jul. 1998). “Stimulation of Tumor Growth by Recombinant Human Insulin-Like Growth Factor-I (IGF-I) Is Dependent on the Dose and the Level of IGF-I Receptor Expression1,”Cancer Res. 58:3021-3027.
Campbell, P. G. et al. (1998). “Plasminogen Binds The Heparin-Binding Domain of Insulin-Like Growth Factor Binding Protein-3,”Am. J. Physiol. 275(Endocrinol. Metab. 38):E321-E331.
Campbell, P.G. et al. (Oct. 1999). “Insulin-Like Growth Factor-Binding Protein-3 Binds Fibrinogen and Fibrin,”The J. of Biol.Chem. 274(42)30215-30221.
Collett-Solberg, P.F. et al. (1998). “Identification of Novel High Molecular Weight Insulin-Like Growth Factor-Binding Protein-3 Association Proteins in Human Serum,”J. of Clin. Endocrinol. and Metab. 83(8):2843-2848.
Durham, S. K.et al. (1999). “The Heparin Binding Domain of Insulin-Like Growth Factor Binding Protein (IGFBP)-3 Increases Susceptibility of IGFBP-3 to Proteolysis,”Horm. Metab. Res. 31:216-225.
Favoni, R. E. et al. (1998). “Modulation of the Insulin-Like Growth Factor-1 System by N-(4-Hydroxyphenyl)-Retinamide in Human Breast Cancer Cell Lines,”Br. J. of Cancer77(12):2138-2147.
Ferry, R. J. Jr. et al. (1999). “Cellular Actions of Insulin-Like Growth Factor Binding Proteins,”Horm. Metab. Res. 31:192-202.
Firth, S. M. et al. (Jan. 1998). “Structural Determinants of Ligand and Cell Surface binding of Insulin-Like Growth Factor-Binding Protein-3,”The J. of Biol. Chem. 273(5):2631-2638.
Fowler, C.A. et al. (1999). “IGFBP-3 and -5 have Opposing Actions on Paclitaxel Induced Apoptosis of Human Breast Cancer Cells,”Growth Hormone and IGF Research9(5):368.
Fowler, C.A. et al. (2000). “Insulin-Like Growth Factor Binding Protein-3 (IGFBP-3) Potentiates Pclitaxel-Induced Apoptosis in Human Breast Cancer Cells,”Int. J. of Cancer88(3): 448-453.
Fowlkes, J. L. and Serra, D.M. (Jun. 1996). “Characterization of Glycosaminoglycan-Binding Domains Present in Insulin-Like Growth Factor-Binding Protein-3,”The J. of Biol. Chem, 271(25):14676-14679.
Gill, Z.P. et al. (Oct. 1997). “Insulin-Like Growth Factor-Binding Protein (IGFBP-3) Prediposes Breast Cancer Cells To Programmed Cell Death In A Non-IGF-Dependent Manner,”The J. of Biol. Chem. 272(41):25602-25607.
Giuliano M, et al. (Jul. 1998). “Induction of Apoptosis in Human Retinoblastoma Cells by Topoisomerase Inhibitors,”Invest. Ophthalmol. &Vis. Sci. 39(8):1300-1311.
Jacques, G. et al. (1997). “Nuclear Localization of Insulin-Like Growth Factor Binding Protein 3 in a Lung Cancer Cell Line,”Endocrinology138(4):1767-1770.
Karas, M et al. (Jun. 1997). “Membrane-Associated Insulin-Like Growth Factor-Binding Protein-3 Inhibits Insulin-Like Growth Factor-I-Induced Insulin-Like Growth-Factor-I Receptor Signaling Ishikawa Endometrial Cancer Cells,”J. Biol. Chem. 272(26):16514-16520.
Kelley, K. W. et al. (1998). “Insulin Growth Factor-I Inhibits Apoptosis in Hematopoietic Progenitor Cells: Implications in Thymic Aginga,”Annals New York Academy of Sciencespp. 518-524.
Leal, S. M. et al. (Aug. 1997). “The Type V Transforming Growth Factor β Receptor is the Putatuve Insulin-Like Growth Factor-Binding 3 Receptor,”The J. of Biol. Chem. 272(33):20572-20576.
Lee, C.Y. and Rechler, M.M. (1995). “Purified Rat Acid-Labile Subunit and Recombinant Human Insulin-Like Growth Factor (IGF)-Binding Protein-3 Can Form a 150-Kilodalton Binary Complex IN Vitro In the Absence of IGF's,”Endocrinology136(11):4982-4989.
Maile, L.A. et al. (1999). “The Role of Cell Surface Attachment and Proteolysis in the Insulin-Like Growth Factor (IGF)-Independent Effects of IGF-Binding Protein-3 on Apoptosis in Breast Epithelial Cells,”Endocrinology140(9):4040-4045.
Nickerson, T. et al. (1997). “Insulin-Like Growth Factor Binding Protein-3 Induces Apoptosis in MCF7 Breast Cancer Cells,”Biochem.and Biophys. Res. Comm. 237(3):690-693.
Pegram, M. D. et al. (Aug. 1998). “Phase II Study of Receptor-Enhanced Chemosensitivity Using Recombinant Humanized Anti-p185HER2
euMonoclonal Antibody Plus Cisplation in Patients With HER2
eu-Overexpressing Metastatic Breast Cancer Refractory to Chemotherapy Treatment,”J. of. Clin. Oncol. 16(8):2659-2671.
Perks, C. M. et al. (1999). “Differential IGF-Independent Effects of Insulin-Like Growth Factor Binding Proteins (1-6) on Apoptosis of Breast Epithelial Cells,”J. of Cell Biochem. 75(4):652-664.
Portera, C.A. Jr. et al. (2000). “Targeting the Insulin-LIke Growth Factor Axis in the Therapy of Colorectal Carcinoma Liver Metastasis,”Growth Hormone&IGF Research10(Supplement A):S47-S48.
Rajah, R.et al. (May 1997). “Insuli
Bioexpertise LLC
Foley & Lardner LLP
Harris Alana M.
Holleran Anne L.
LandOfFree
Method for use of IGF-binding protein for selective... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for use of IGF-binding protein for selective..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for use of IGF-binding protein for selective... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2777169